Amgen Inc. News Highlights – 23 October 2025

Amgen Inc. (NASDAQ: AMGN), an independent biotechnology company specializing in human therapeutics, was the subject of several significant developments during the week of 23 October 2025. The company’s share price closed at $295.98 on 21 October, within its 52‑week range of $253.30 to $335.88.

1. Shareholder Rights Inquiry

  • Halper Sadeh LLC announced on 23 October that it is investigating potential breaches of fiduciary duty by certain Amgen officers and directors.
  • The investigation focuses on shareholders who acquired Amgen shares on or before 29 July 2020.
  • Shareholders may be eligible for corporate governance reforms, the return of funds to the company, a court‑approved financial incentive award, or other relief.
  • The firm urges affected shareholders to contact it for information on legal rights and options.

2. Regulatory Approval for Tezspire

  • On 22 October, AstraZeneca and Amgen received European Union approval for Tezspire (tezepelumab) as an add‑on therapy with intranasal corticosteroids.
  • The indication targets adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard treatments such as systemic corticosteroids or surgery.
  • The approval expands Amgen’s portfolio in the respiratory therapeutics market, which serves an estimated 320 million worldwide patients.

3. Thrombocytopenia Market Report

  • A market research release from 21 October highlighted Amgen as a key player in the global thrombocytopenia management market.
  • The report, produced by DataM Intelligence, projects significant growth in the TPO‑RA and targeted therapy segments through 2033.
  • Amgen’s involvement in this market underscores its strategic focus on platelet‑related disorders.

4. Market Context

  • The broader equity market showed modest gains on 23 October.
  • The Nasdaq Composite increased by 0.11 %, reflecting a slight lift in technology and biotech stocks, including Amgen.
  • Global indices such as the Dow Jones Industrial Average and S&P 500 posted small gains earlier in the day, providing a supportive backdrop for Amgen’s share performance.

Key Takeaways

  • Governance Concerns: Halper Sadeh’s investigation may prompt shareholder activism and potential regulatory scrutiny.
  • Product Expansion: EU approval of Tezspire extends Amgen’s therapeutic reach into severe nasal polyps, potentially driving revenue growth.
  • Market Position: Amgen’s recognition in the thrombocytopenia market report highlights its continued commitment to platelet‑related therapies.
  • Stock Performance: Amgen’s share price remained stable within its 52‑week range, supported by positive market sentiment in the Nasdaq sector.

These events collectively shape Amgen’s strategic trajectory, regulatory standing, and shareholder relations as it navigates the evolving biopharmaceutical landscape.